Skip to main content
  • Report an Adverse Event
  • Locate an MSL
RNAiScience logo
Search Menu
  • Home
  • Alnylam & RNAi
  • Congresses & Publications
  • Therapeutic Areas
  • Our Therapies
  • Pipeline & Clinical Trials
  • Connect With Us
  • Payer Connect
  • Log in
  • Sign Up
Alnylam logo
  • Privacy Policy
  • |
  • Terms of Use
| © 2025 Alnylam

This site is intended for US healthcare professionals.
© 2025 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

RNAiScience logo
  • Home
  • Alnylam & RNAi
  • Congresses & Publications
  • Therapeutic Areas
  • Our Therapies
  • Pipeline & Clinical Trials
  • Connect With Us
  • Payer Connect
Alnylam logo
  • Privacy Policy
  • |
  • Terms of Use

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

  • Report an Adverse Event
  • Locate an MSL
  • Log in
|
  • Sign Up

Search Results for "amyloidosis"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited. 

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

  • AMVUTTRA® (vutrisiran)
  • GIVLAARI® (givosiran)
  • ONPATTRO® (patisiran)
  • OXLUMO® (lumasiran)

Outpatient Heart Failure Worsening in Patients with Cardiac Transthyretin Amyloidosis: Results from the APOLLO-B Trial This link is a pdf
Bookmark this pageBookmark this page

Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study This link is a pdf

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study This link is a pdf

APOLLO Post-Hoc Analysis by Baseline Polyneuropathy Severity This link is a pdf
Bookmark this pageBookmark this page

A post-hoc analysis of the APOLLO trial was performed to evaluate the use of patisiran compared to placebo by baseline NIS quartile in patients with the the polyneuropathy of hATTR. This infographic summarizes the post-hoc analysis results, which were published in the journal Amyloid.

Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial This link is a pdf

HELIOS-A: Efficacy and safety of vutrisiran in patients with hATTR with polyneuropathy This link is a pdf
Bookmark this pageBookmark this page

Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.

Meta-regression analysis of the association between change in six minute walk distance and survival in transthyretin-mediated amyloidosis with cardiomyopathy This link is a pdf
Bookmark this pageBookmark this page

Impact of vutrisiran on outpatient worsening heart failure in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial This link is a pdf
Bookmark this pageBookmark this page

Hereditary ATTR Amyloidosis: A Closer Look at the V122I Variant External This link is a pdf
Bookmark this pageBookmark this page

V122I is the most common variant of hATTR amyloidosis in the United States and is most prevalent in patients of African American descent. Compared to other variants, patients with the V122I variant experience significant disease burden and poorer outcomes.

Effect and Safety of Patisiran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy and Chronic Kidney Disease Results This link is a pdf
Bookmark this pageBookmark this page

Pagination

  • 1 of 10
  • Next page

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

This site is intended for US healthcare professionals.
© 2025 Alnylam Pharmaceuticals, Inc. All rights reserved.
MED-US-ALL-2400001

  • Privacy Policy
  • |
  • Terms of Use
| © 2025 Alnylam
Alnylam logo
RNAI Logo

You are now leaving this site and being directed to a third-party website that is not maintained by Alnylam. Alnylam does not endorse and is not responsible for content or maintenance of third-party websites.

ContinueCancel

RNAI Logo

You are now leaving this site and being directed to another Alnylam website.

ContinueCancel

RNAI Logo

Intended for US healthcare professionals. This site is intended to provide balanced, evidence-based information to support scientific exchange. It is not intended to provide medical advice or recommendations for clinical practice.

Information about investigational therapeutics or investigational uses of approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of FDA approval.

Alnylam does not recommend or suggest use of its products in any manner inconsistent with the approved Prescribing Information.

Are you a healthcare professional practicing in the United States?

I confirm I am a US healthcare professional

I am a US payer or healthcare decision maker

I am not a US healthcare professional, or a US payer or healthcare decision maker

I am an Alnylam Team Member

X
Don't miss out!

Sign in to bookmark information and create your personal library

Log in

Don't have an account? Sign up